Morepen Laboratories Ltd

- Currently, there is no immediate plan for new acquisitions or fundraising through equity as the recent QIP of INR 200 crores was primarily for capex and working capital. - The company is evaluating multiple acquisition opportunities but will consider them only if they add synergy and align with strategy. - No immediate debt raise is planned; Morepen Laboratories is currently a debt-free company. - The capital raised in the recent QIP is targeted mainly for capacity expansion in APIs and medical devices. - Future fundraising through debt or equity will depend on cash surplus and strategic needs, but no specific plans have been announced at this time.

- Currently, Morepen Laboratories has planned a capex of INR 123 crores. - Of this, approximately INR 78 crores is allocated for API capacity expansion (from 400 KL to 600 KL). - Around INR 40-45 crores is earmarked for medical devices, including backward integration and capacity expansion for glucometers, BP monitors, and weighing scales. - Backward integration projects, such as chip manufacturing for medical devices, are underway and expected to show results from Q3/Q4 FY '25. - The company is focused on expanding distribution reach across India (especially South and West regions) and tapping into global export markets. - Though there is no immediate plan for acquisitions, the company remains open to synergistic acquisitions if suitable opportunities arise. - The capital raised through QIP (approx. INR 200 crores) primarily supports these capex plans with a focus on sustained revenue growth (estimated 15%-20% annually) and margin improvement.

- The company expects to maintain at least 15% to 18% revenue growth. - Revenue growth is anticipated to be steady between 15% to 20% annually. - Medical devices segment is the fastest growing business, with a CAGR of around 20%-25%, expected to continue. - Expansion plans to increase retail outlets from 128,000 to 300,000 across India within three years to boost sales. - Focus on backward integration and capacity expansion to support volume growth in glucometers, BP monitors, and APIs. - International market penetration is targeted within 2-3 years to significantly enhance growth prospects. - New launches planned, including a weight loss OTC product, aiming to capture emerging market segments. - EBITDA margins expected to improve by 3% to 4% over the next 2-3 years, supporting profitability alongside revenue growth. - Export markets, especially Europe and Asia Pacific, showing strong growth potential with ongoing capacity enhancement.

- The company expects to maintain 15% to 18% revenue growth going forward. - EBITDA margins are targeted to improve by 3% to 4% over the next 2-3 years, moving from around 12% currently to approximately 15%. - The aim is to reach EBITDA margins of 12% to 15% over the next three years to align with industry norms. - Profit After Tax (PAT) is expected to gradually increase towards double-digit levels, with current quarterly PAT at 7.89%. - Earnings Per Share (EPS) for the trailing 12 months has risen to INR 2.30, reflecting strong growth. - The company is focused on revenue CAGR of 15% to 20%, supported by capacity expansions in APIs and medical devices. - Medical devices segment is expected to grow at a CAGR of 20%-25%. - Overall, the company is on a growth trajectory with steady margin expansion and increasing return on capital employed.

- The transcript does not explicitly mention the current or expected order book or pending orders for Morepen Laboratories Limited. - However, there is discussion about capacity expansion plans, including a capex of INR123 crores for APIs and medical devices, indicating anticipation of increased demand. - The company mentions being short of capacities, especially in medical devices, which implies strong order inflow. - They have increased distribution reach, targeting expansion in Indian markets and exploring exports, suggesting a growing pipeline. - No specific figures on order backlog or pending orders were provided during the Q&A.